Epistem to exhibit at IID, Kyoto Japan May 2008
08/05 11:00 (Epistem Ltd)
From May 14-17, Epistem will be exhibiting at the 5th Joint Meeting of the European Society for Dermatological Research (ESDR) Japanese Society for Investigative Dermatology (JSID), Society for Investigative Dermatology (SID) in Kyoto, Japan . Epistem will be exhibiting its portfolio of dermatology research services (Booth #8).

Epistem to provide preclinical efficacy testing for EBI
24/04 18:24 (Drug Discovery News)
MANCHESTER, U.K.-Epistem announced recently that (EBI) has contracted Epistem to provide their specialized preclinical efficacy testing services for agents likely to protect the gastrointestinal tract against radiation...

Stem Cells: The Role of Cancer-Initiating Cells in Diagnosis and Treatment
17/04 19:26 (Pharma Live)
Recent discoveries about the role of stem cells in cancer have altered the landscape of cancer research. As scientists learn more their cancer-initiating properties, stem cells are emerging as potential therapeutic targets for many types of cancers.

EPISTEM TO RELEASE DATA ON ITS CANCER STEM CELL ASSAYS AT AACR
07/04 14:42 ()
Epistem plc (LSE: EHP), the UK epithelial stem cell company, announced today that data on its cancer stem cell assays will be presented at the international meeting of the American Association for Cancer Research (AACR) at the San Diego Convention Centre, California, USA from 13th to 16th April 2008.

Epistem strengthens management team with the appointment of Lydia Meyer-Turkson as Director of Biomarkers Division
06/03 13:15 (LSE)
Epistem is pleased to announce the appointment of Lydia Meyer-Turkson as Director of it's emerging Biomarker Division. Lydia will lead the continued expansion of the division managing strategic collaborations with Pharmaceutical and Biotechnology companies using Epistem's plucked hair biomarker technology.

Sales soar 66pc at Epistem
29/02 08:42 (Manchester Evening News)
Do you believe that more legislation is the answer to getting businesses and consumers to cut their carbon emissions? Contact us : : : : Privacy policy : Help : Archive : Home...

EpiStem Holdings plc - Interim Results
28/02 08:46 (Selftrade)
RNS Number:8991O EpiStem Holdings plc 28 February 2008 For release: 28th February 2008 Epistem Plc (LSE: EHP), the UK epithelial stem cell company, announced today its interim results for the period to 31st December...

Targeted Therapies for Gastrointestinal Cancer
06/02 18:15 (Epistem Manchester UK)
Epistem will be attending and speaking at the Targeted Therapies for Gastrointestinal Cancer on March 14th 2008 at the New York Academy of Sciences.

Epistem Plc and AstraZeneca complete plucked hair biomarker study for oncology drug development
28/01 10:56 (Epistem Manchester UK)
Epistem plc (LSE:EHP) announced today that it had successfully completed a preliminary study with AstraZeneca for the use of its proprietary, minimally invasive plucked human hair biomarker technology to help steer oncology drug development.

EpiStem raises 1.07 mln stg to accelerate gene expression biomarker technology
20/11 17:36 (Yahoo Finance)
| | | LONDON (Thomson Financial) - EpiStem Holdings PLC said it has raised about 1.07 mln stg via a placing of 653,806 shares at 1.63 stg each, to accelerate the development of its high-sensitivity gene expression biomarker technology.

EpiStem Holdings - Preliminary Results
10/10 07:48 (Hemscott)
RNS Number:4421F EpiStem Holdings plc 10 October 2007 Preliminary Results to 30th June 2007 Epistem Holdings Plc (LSE: EHP), the UK epithelial stem cell company, announced today its preliminary results for the period to 30th June 2007.